Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (COVID-19)

June 16, 2023 updated by: China National Biotec Group Company Limited

Safety and Immunogenicity Study on Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above Vaccinated the Prototype Inactivated COVID-19 Vaccine

This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd. According to subject's age (18-59 vs 60 and above), doses of vaccination history ( 2 doses vs 3 doses), and vaccination interval, the subjects will be stratified and assigned randomly to the study groups ( Omicron inactivated COVID-19 Vaccine) or the control groups ( Prototype inactivated COVID-19 Vaccine) in a 2:1 ratio. All subjects will receive single dose or two doses of vaccine with a interval of 28 days. The occurrence of adverse events within 28 days and serious adverse events within 12 months after vaccination will be observed. The serum antibody levels, cellular immune responses will be analyzed at different time points.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
4200

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Junshi Zhao, Master
  • Phone Number: +8617788903138
  • Email: ymlc02@hncdc.com

Study Locations

  • China
    • Hunan
      • Changde, Hunan, China, 415200
        • Linli County Center for Disease Control and Prevention
      • Changning, Hunan, China, 421500
        • Changning Center for Disease Control and Prevention
      • Changsha, Hunan, China
        • Ningxiang Center for Disease Control and Prevention
      • Changsha, Hunan, China
        • Outpatient Department of Hunan Provincial Center For Disease Control And Prevention
      • Loudi, Hunan, China
        • Loudi Public Health Hospital
      • Xiangtan, Hunan, China
        • Xiangtan Center For Disease Control And Prevention
      • Xiangxi, Hunan, China
        • Luxi County Center for Disease Control and Prevention
      • Xiangxiang, Hunan, China
        • Xiangxiang Center for Disease Control and Prevention
      • Yueyang, Hunan, China
        • Huarong County Center for Disease Control and Prevention
      • Zhuzhou, Hunan, China, 412300
        • You County Center for Disease Control and Prevention

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy subjects aged 18 years old and above.
  • By asking for medical history and physical examination, the investigator judged that the health condition is well.
  • Has been vaccinated 2 or 3 doses of inactivated COVID-19 vaccine manufactured by BIBP more than 3 months.
  • Female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 12 months after enrolment. Effective contraceptive measures have been taken within 2 weeks before inclusion.
  • During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan.
  • With self-ability to understand the study procedures, the informed consent & voluntarily sign an informed consent form and be able to comply with the requirements of the clinical study protocol.

Exclusion Criteria:

  • Confirmed or suspected cases of SARS-CoV-2 Infection.
  • Has a history of SARS, MERS, SARS-CoV-2 infection (self-report, on-site inquiry).
  • Received one dose or more than 3 doses of inactivated COVID-19 vaccine manufactured by BIBP
  • Received COVID-19 vaccine manufactured bu other companies (include mRNA, recombinant protein vaccines, vector vaccines, inactivated vaccines, etc.)
  • Axillary body temperature > 37.3 ℃ before vaccination
  • Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated SARS-CoV-2 vaccine have occurred (self-report, on-site inquiry).
  • History of hospital-diagnosed thrombocytopenia or other coagulation disorder
  • Known immunological impairment or low level with hospital diagnosis
  • History of uncontrolled epilepsy, other progressive neurological disorders, or Guillain-Barre syndrome (self-report, on-site inquiry).
  • Known or suspected concomitant serious diseases include: respiratory disease, acute infection or active chronic disease, liver and kidney disease, severe diabetes, malignant tumor, infection or allergic skin disease, HIV infection.
  • Severe cardiovascular disease (cardiopulmonary failure, uncontrolled hypertension, etc.) diagnosed by the hospital, active chronic respiratory disease
  • Received live attenuated vaccine within 1 month before enrollment.
  • Received other vaccines within 14 days before enrollment.
  • Be participating in or plan to participate in other vaccine clinical trials during this study.
  • Contraindications related to vaccination as considered by other investigators.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: A1：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: A2：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: A3：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: A4：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: B1：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: B2：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: B3：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: B4：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: C1：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: C2：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: C3：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: C4：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: C5：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: C6：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: D1：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: D2：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: D3：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: D4：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: E1：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: E2：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: E3：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: E4：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: E5：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: E6：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination
subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: F1：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: F2：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Experimental: F3：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle
Active Comparator: F4：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination
subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
intramuscular injection in the deltoid muscle

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
The Geometric Mean Titer (GMT) of neutralizing antibody against Omicron SARS-CoV-2
Time Frame: On Day 28 after vaccination
On Day 28 after vaccination
The four-fold increase rate of neutralizing antibody against Omicron SARS-CoV-2
Time Frame: On Day 28 after vaccination
On Day 28 after vaccination
Incidence of adverse reactions
Time Frame: within 28 days after vaccination
within 28 days after vaccination

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Specific cellular immune response
Time Frame: within 28 days after vaccination
within 28 days after vaccination
The proportion of subjects with neutralizing antibody GMT ≥1:16，≥1:32 and ≥1:64
Time Frame: on 3rd month, 6th month, 9th month, and 12th month after vaccination
on 3rd month, 6th month, 9th month, and 12th month after vaccination
The incidence of any adverse reactions/events
Time Frame: 28 days after each immunization
28 days after each immunization
The GMT of neutralizing antibody against Omicron SARS-CoV-2
Time Frame: On Day 14 after vaccination
On Day 14 after vaccination
The four-fold increase rate of neutralizing antibody against Omicron SARS-CoV-2
Time Frame: On Day 14 after vaccination
On Day 14 after vaccination
The neutralizing antibody GMT
Time Frame: on 3rd month, 6th month, 9th month, and 12th month after vaccination
on 3rd month, 6th month, 9th month, and 12th month after vaccination
The incidence of serious adverse events (SAE) and adverse events special interest (AESI)
Time Frame: From the beginning of the first dose to 12 months after vaccination
From the beginning of the first dose to 12 months after vaccination

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Time Frame
The incidence of COVID-19 cases , including severe cases and deaths accompanied by COVID-19
Time Frame: From 14 day after vaccination
From 14 day after vaccination
The neutralizing antibody GMT to different variants of SARS-CoV-2
Time Frame: On Day 28 after vaccination
On Day 28 after vaccination
The IgG antibody lever against Omicron SARS-CoV-2
Time Frame: On Day 14 and Day 28 after vaccination
On Day 14 and Day 28 after vaccination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
China National Biotec Group Company Limited

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Beijing Institute of Biological Products Co Ltd.
Hunan Provincial Center for Disease Control and Prevention

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 10, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 25, 2022

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 10, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 13, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 16, 2022

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 19, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CNBG-BIBP-O-2022004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings